*~
Alloclassic® - Clinical Experience
|
Year
|
Author
|
Clinical Cases
|
Follow-up
(years)
|
Survival Rate
|
|
1995
|
Havelin et al. MC
|
333 avg.
|
3.9
|
99.1%
|
|
1995
|
Huo et al.
|
46 avg.
|
4.2
|
100%
|
|
1995
|
Baumgartner et al.
|
533 max.
|
7
|
98.9%
|
|
1995
|
Bohler et al.
|
104 avg.
|
4.3
|
100%
|
|
1996
|
Delaunay & Kapandji
|
167 max.
|
8
|
99.3%
|
|
1996
|
Love
|
25 max.
|
7
|
100%
|
|
1997
|
Dorig et al.
|
331 max.
|
8
|
100%
|
|
1998
|
Delaunay et al.
|
116 max.
|
8
|
99.3%
|
|
Excellent clinical results are the reason the Alloclassic is the most
widely used cementless hip stem in Europe and on its way to broad market
acceptance in the United States.
